Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics
Callie M. Blase1, Brandon K. Rouault1, Maia B. Zoller1, Joshua V. Luff1, Emma J. Lerch1, Brynn N. Lauterbachq1, Mark A. Brown1, Joachim Storsberg2 & Christian Schmidt2 Show affiliations
- Colorado State University, United States
- Fraunhofer-Institute for Applied Polymer Research , Germany
American Journal of Immunology, Volume 15, Issue 1, pp. 19–21 · doi.org/10.3844/ajisp.2019.19.21
Abstract
The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Blase, C. M., Rouault, B. K., Zoller, M. B., Luff, J. V., Lerch, E. J., Lauterbachq, B. N., Brown, M. A., Storsberg, J. & Schmidt, C. (2019). Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics. American Journal of Immunology, 15(1), 19–21. https://doi.org/10.3844/ajisp.2019.19.21
- Licence
- CC BY 3.0
- Issue
- Volume 15, Issue 1
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record